In early trials, an experimental abdominal injection reduced visceral fat; the analyzed group averaged about 36 to 42 years old

What the research found

Study (phase 2 meeting analysis of an experimental drug, plus separate animal work). ScienceDaily carried the European Association for the Study of Diabetes account on 11 October 2026 from the annual meeting in Milan. W. Timothy Garvey of the University of Alabama at Birmingham and Yu-Fang Ling of Caliway Biopharmaceuticals described CBL-514, an injection meant to make fat cells die rather than only empty them. 6 percent of people on CBL-514 had lost at least 150 mL of subcutaneous fat volume at eight weeks, and none on placebo reached that mark. A pooled look at MRI subsets from trials CBL-0204 and CBL-0205 included people with body mass index 22 to 30 who had injections in the lower abdomen every three weeks for up to 12 weeks, up to 600 mg (23 on the drug, 17 on placebo at the later scan). 4 years. Of the 23 on the drug, 17 were women and 6 were men. 81 mL on placebo. 68 percent above baseline on placebo. 76 percent above on placebo. Most side effects were mild or moderate pain, swelling, or redness at the injection site. No serious adverse events were reported in that account. Separate animal work, not the human MRI analysis, found less weight regain after tirzepatide was stopped when CBL-514 had been added. The release names Ozempic, Wegovy, Mounjaro, and Zepbound as the GLP-1 receptor agonist setting for that question and says the regain finding is not yet shown in people. Phase 3 recruitment was underway. Garvey said cosmetic flattening is not the health endpoint. Educational notes. CBL-514 is experimental. It is not a supplement, not a substitute for a prescribed medicine, and not something to start from a headline. Off-label or unapproved use is clinician-only and, here, still a trial question.

Evidence level: Clinical trial. This is among the stronger kinds of evidence, but one study rarely settles a question.

Not medical advice. Not a substitute for a prescribed medicine. Off-label prescription use is clinician-only. VitaLonga does not diagnose, treat, or cure disease. Never start, stop, or replace a prescription with a supplement on the basis of a headline.

Read the original at European Association for the Study of Diabetes